Dr Massimo Martino

All Stories

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma

Article • Cancers, August 2026, MDPI AG

Dr Massimo Martino
Outcomes of CAR T‐Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Article • European Journal of Cancer, August 2026, Elsevier

Dr Massimo Martino
Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

Article • British Journal of Pharmacology, July 2026, Springer Science + Business Media

Dr Massimo Martino
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society f...

Article • British Journal of Pharmacology, July 2026, Springer Science + Business Media

Dr Massimo Martino
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first comple...

Article • British Journal of Pharmacology, June 2026, Springer Science + Business Media

Dr Massimo Martino
Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms

Article • Journal of Clinical Medicine, June 2026, MDPI AG

Dr Massimo Martino
Quality of Life in CAR-T Cell Therapy

Article • Hematology Reports, June 2026, MDPI AG

Dr Massimo Martino
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study

Article • Blood Advances, May 2026, American Society of Hematology

Dr Massimo Martino
Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing

Article • Expert Review of Hematology, March 2026, Taylor & Francis

Dr Massimo Martino
A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML

Article • Cancers, February 2026, MDPI AG

Dr Massimo Martino
Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care

Article • Cancers, February 2026, MDPI AG

Dr Massimo Martino
Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?

Article • Cancers, December 2025, MDPI AG

Dr Massimo Martino
Efficacy of Polyvinylpyrrolidone–Zinc Gluconate and Taurine Gel in the Prophylaxis of Oral Mucositis in Adults Undergoing High-Dose Chemotherapy and Allogeneic Stem Cell Transplantation

Article • Diseases, December 2025, MDPI AG

Dr Massimo Martino
Harnessing Venetoclax in NPM1-Mutated AML: A Path to Sustained Remission and Beyond

Article • Cancers, November 2025, MDPI AG

Dr Massimo Martino
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus

Article • Cytotherapy, November 2025, Elsevier

Dr Massimo Martino
SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma

Article • Cancers, October 2025, MDPI AG

Dr Massimo Martino
The Evolving Role of Hematopoietic Stem Cell Transplantation in Philadelphia-like Acute Lymphoblastic Leukemia: From High-Risk Standard to Precision Strategies

Article • Cancers, October 2025, MDPI AG

Dr Massimo Martino
CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues

Article • Cancers, September 2025, MDPI AG

Dr Massimo Martino
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy

Article • Cancers, August 2025, MDPI AG

Dr Massimo Martino
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study

Article • British Journal of Pharmacology, February 2025, Springer Science + Business Media

Dr Massimo Martino
Treatment Strategies Used in Treating Myelofibrosis: State of the Art

Article • Hematology Reports, October 2024, MDPI AG

Dr Massimo Martino
First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study

Article • Cancers, September 2024, MDPI AG

Dr Massimo Martino
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Article • Expert Review of Hematology, May 2024, Taylor & Francis

Dr Massimo Martino
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)

Article • British Journal of Pharmacology, May 2024, Springer Science + Business Media

Dr Massimo Martino
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning

Article • Expert Opinion on Biological Therapy, December 2023, Taylor & Francis

Dr Massimo Martino
The Role of MicroRNA in Graft-Versus-Host-Disease: A Review

Article • Genes, September 2023, MDPI AG

Dr Massimo Martino
Refractory CMV infection in post-transplant phase: epidemiological framing in the Italian context, current patient management and unmet needs

Article • AboutOpen, June 2023, Aboutscience Srl

Dr Massimo Martino
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Article • Annals of Hematology, June 2023, Springer Science + Business Media

Dr Massimo Martino
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Article • Annals of Hematology, April 2023, Springer Science + Business Media

Dr Massimo Martino
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Article • Nature Medicine, April 2023, Springer Science + Business Media

Dr Massimo Martino
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party

Article • British Journal of Pharmacology, February 2023, Springer Science + Business Media

Dr Massimo Martino
Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?

Article • International Journal of Molecular Sciences, January 2023, MDPI AG

Dr Massimo Martino
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Article • International Journal of Molecular Sciences, November 2022, MDPI AG

Dr Massimo Martino
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

Article • British Journal of Pharmacology, September 2022, Springer Science + Business Media

Dr Massimo Martino
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT

Article • British Journal of Pharmacology, June 2022, Springer Science + Business Media

Dr Massimo Martino
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Article • Hematological Oncology, June 2022, Wiley

Dr Massimo Martino
Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation

Article • British Journal of Pharmacology, April 2022, Springer Science + Business Media

Dr Massimo Martino
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01

Article • British Journal of Pharmacology, April 2022, Springer Science + Business Media

Dr Massimo Martino
Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

Article • Farmeconomia Health economics and therapeutic pathways, February 2022, Seed SRL

Dr Massimo Martino
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms

Article • Transplantation and Cellular Therapy, February 2022, Elsevier

Dr Massimo Martino
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Article • British Journal of Pharmacology, January 2022, Springer Science + Business Media

Dr Massimo Martino
The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML

Article • British Journal of Pharmacology, January 2022, Springer Science + Business Media

Dr Massimo Martino
Biological Significance and Prognostic Value of Cytogenetics in 160 Patients with Multiple Myeloma: Predictivity of 13 and/or 14 Monosomies

Article • Blood, November 2021, American Society of Hematology

Dr Massimo Martino
Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Article • Blood, November 2021, American Society of Hematology

Dr Massimo Martino
Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Article • Blood, November 2021, American Society of Hematology

Dr Massimo Martino
Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Article • Blood, November 2021, American Society of Hematology

Dr Massimo Martino
Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Article • Blood, November 2021, American Society of Hematology

Dr Massimo Martino
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Article • Transplantation and Cellular Therapy, November 2021, Elsevier

Dr Massimo Martino
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study

Article • British Journal of Pharmacology, October 2021, Springer Science + Business Media

Dr Massimo Martino
Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Article • Expert Opinion on Biological Therapy, September 2021, Taylor & Francis

Dr Massimo Martino
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

Article • Frontiers in Oncology, September 2021, Frontiers

Dr Massimo Martino
The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo

Article • Journal of Clinical Pharmacy and Therapeutics, August 2021, Wiley

Dr Massimo Martino
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Article • Supportive Care in Cancer, August 2021, Springer Science + Business Media

Dr Massimo Martino
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

Article • Drug Design Development and Therapy, July 2021, Taylor & Francis

Dr Massimo Martino
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Article • Cancers, May 2021, MDPI AG

Dr Massimo Martino
Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellular...

Article • Transplantation and Cellular Therapy, May 2021, Elsevier

Dr Massimo Martino
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study

Article • International Journal of Hematology, April 2021, Springer Science + Business Media

Dr Massimo Martino
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)

Article • British Journal of Pharmacology, April 2021, Springer Science + Business Media

Dr Massimo Martino
The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation

Article • Clinical Lymphoma Myeloma & Leukemia, April 2021, Elsevier

Dr Massimo Martino
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study

Article • Annals of Hematology, March 2021, Springer Science + Business Media

Dr Massimo Martino
Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT

Article • British Journal of Pharmacology, March 2021, Springer Science + Business Media

Dr Massimo Martino
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study

Article • Transplantation and Cellular Therapy, March 2021, Elsevier

Dr Massimo Martino
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia

Article • International Journal of Molecular Sciences, February 2021, MDPI AG

Dr Massimo Martino
Chemotherapy-based regimens in multiple myeloma in 2020

Article • Panminerva Medica, February 2021, Edizioni Minerva Medica

Dr Massimo Martino
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

Article • Journal for ImmunoTherapy of Cancer, February 2021, BMJ

Claudio Tripodo, Dr Massimo Martino
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Article • Expert Opinion on Biological Therapy, January 2021, Taylor & Francis

Dr Massimo Martino
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

Article • Panminerva Medica, January 2021, Edizioni Minerva Medica

Dr Massimo Martino
Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission

Article • British Journal of Pharmacology, December 2020, Springer Science + Business Media

Dr Massimo Martino
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety

Article • Transfusion and Apheresis Science, December 2020, Elsevier

Dr Massimo Martino
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art

Article • Frontiers in Oncology, November 2020, Frontiers

Dr Massimo Martino
A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma

Article • Blood, November 2020, American Society of Hematology

Dr Massimo Martino
Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Article • Blood, November 2020, American Society of Hematology

Dr Massimo Martino
Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Article • Blood, November 2020, American Society of Hematology

Dr Massimo Martino
A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis

Article • Transfusion and Apheresis Science, October 2020, Elsevier

Dr Massimo Martino
Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy

Article • Blood Advances, August 2020, American Society of Hematology

Dr Massimo Martino
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report

Article • Frontiers in Oncology, June 2020, Frontiers

Dr Massimo Martino
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia

Article • Leukemia, May 2020, Springer Science + Business Media

Dr Massimo Martino
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Article • Biology of Blood and Marrow Transplantation, May 2020, Elsevier

Dr Massimo Martino
Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)

Article • British Journal of Pharmacology, April 2020, Springer Science + Business Media

Dr Massimo Martino
Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: A survey by GITMO, SIDEM and GIIMA societies

Article • Transfusion and Apheresis Science, April 2020, Elsevier

Dr Massimo Martino
Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab

Article • British Journal of Pharmacology, March 2020, Springer Science + Business Media

Dr Massimo Martino
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Article • Haematologica, February 2020, Ferrata Storti Foundation (Haematologica)

Dr Massimo Martino
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost

Article • Leukemia Research Reports, January 2020, Elsevier

Dr Massimo Martino
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Article • Annals of Hematology, December 2019, Springer Science + Business Media

Dr Massimo Martino
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Article • Expert Opinion on Pharmacotherapy, November 2019, Taylor & Francis

Dr Massimo Martino
Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Article • Blood, November 2019, American Society of Hematology

Dr Massimo Martino
Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Article • Biology of Blood and Marrow Transplantation, August 2019, Elsevier

Dr Massimo Martino
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

Article • Expert Review of Hematology, July 2019, Taylor & Francis

Dr Massimo Martino, marco rossi
Individualized prediction of leukemia‐free survival after autologous stem cell transplantation in acute myeloid leukemia

Article • Cancer, June 2019, Wiley

Dr Massimo Martino
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

Article • Blood Advances, April 2019, American Society of Hematology

Dr Alejandro Lazo-Langner, Dr Massimo Martino
The use of ibrutinib before and after allogeneic stem cell transplantation

Article • Expert Opinion on Orphan Drugs, April 2019, Taylor & Francis

Dr Massimo Martino, Fabio Provenzano
Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Article • Blood, November 2018, American Society of Hematology

Dr Massimo Martino
Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT

Article • Blood, November 2018, American Society of Hematology

Dr Massimo Martino
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score

Article • British Journal of Pharmacology, January 2018, Springer Science + Business Media

Dr Massimo Martino
Venetoclax for the treatment of chronic lymphocytic leukemia

Article • Expert Opinion on Investigational Drugs, October 2017, Taylor & Francis

Dr Massimo Martino
Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?

Article • Expert Opinion on Orphan Drugs, October 2017, Taylor & Francis

Dr Massimo Martino
A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model

Article • Biology of Blood and Marrow Transplantation, October 2017, Elsevier

Dr Massimo Martino
Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model

Article • Clinical Lymphoma Myeloma & Leukemia, August 2017, Elsevier

Dr Massimo Martino
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach

Article • American Journal of Hematology, July 2017, Wiley

Dr Massimo Martino
Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma

Article • Leukemia & Lymphoma, June 2017, Taylor & Francis

Dr Massimo Martino
Chemotherapy and Cardiotoxicity in Hematologic Malignancies

Article • Current Cancer Drug Targets, April 2017, Bentham Science Publishers

Dr Massimo Martino
Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of G-CSF: a Longitudinal, Prospective, Observational, Single-Center, Cohort Study

Article • Biology of Blood and Marrow Transplantation, March 2017, Elsevier

Dr Massimo Martino
Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012

Article • Clinical Genitourinary Cancer, February 2017, Elsevier

Dr Massimo Martino
Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation

Article • Expert Opinion on Biological Therapy, September 2016, Taylor & Francis

Dr Massimo Martino
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy

Article • British Journal of Pharmacology, April 2016, Nature

Dr Massimo Martino
Sorafenib for the treatment of multiple myeloma

Article • Expert Opinion on Investigational Drugs, April 2016, Informa Healthcare

Dr Massimo Martino
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma

Article • British Journal of Pharmacology, April 2016, Nature

Dr Massimo Martino
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma

Article • Journal of Hematology & Oncology, March 2016, Springer Science + Business Media

Dr Massimo Martino
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

Article • Biology of Blood and Marrow Transplantation, March 2016, Elsevier

Dr Massimo Martino
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents

Article • Expert Opinion on Biological Therapy, February 2016, Informa Healthcare

Dr Massimo Martino
The role of tandem stem cell transplantation for multiple myeloma patients

Article • Expert Opinion on Biological Therapy, February 2016, Informa Healthcare

Dr Massimo Martino
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantatio...

Article • British Journal of Pharmacology, December 2015, Nature

Dr Massimo Martino
A Phase 2 Study of Bendamustine Plus Melphalan Conditioning for Second Autologous Stem Cell Transplantation in "De-Novo" Multiple Myeloma Patients in a Tandem Transplant Strategy

Article • Blood, December 2015, American Society of Hematology

Dr Massimo Martino
Fast and Non-Invasive Identification of Tumorigenic-Proliferative Biomarker in Myeloproliferative and Lymphoproliferative Disorders

Article • Blood, December 2015, American Society of Hematology

Dr Massimo Martino
Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma

Article • Blood, December 2015, American Society of Hematology

Dr Massimo Martino
High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study

Article • Biology of Blood and Marrow Transplantation, November 2015, Elsevier

Dr Massimo Martino
Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy

Article • Leukemia & Lymphoma, October 2015, Informa Healthcare

Dr Massimo Martino
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients

Article • Cytotherapy, October 2015, Elsevier

Massimo Martino, Dr Massimo Martino
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights

Article • Tumor Biology, August 2015, Springer Science + Business Media

Dr Massimo Martino
Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age

Article • Biology of Blood and Marrow Transplantation, May 2015, Elsevier

Dr Massimo Martino
High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer

Article • JNCI Monographs, May 2015, Oxford University Press (OUP)

Dr Massimo Martino
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity

Article • Expert Review of Anticancer Therapy, April 2015, Taylor & Francis

Dr Massimo Martino
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs

Article • Expert Opinion on Biological Therapy, April 2015, Informa Healthcare

Dr Massimo Martino
Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control

Article • Transfusion, April 2015, Wiley

Dr Massimo Martino
Smoldering multiple myeloma: to treat or not to treat

Article • Expert Opinion on Pharmacotherapy, February 2015, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

Article • Journal of Immunology Research, January 2015, Hindawi Publishing Corporation

Dr Massimo Martino
Bendamustine Plus Melphalan As Conditioning Regimen for Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Single Centre Experience

Article • Blood, December 2014, American Society of Hematology

Dr Massimo Martino
Biosimilar Compared with Originator Filgrastim for Autologous Stems CELL Mobilisation: A Prospective-Historical Control Study in Multiple Myeloma REAL-Life Setting

Article • Blood, December 2014, American Society of Hematology

Dr Massimo Martino
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma

Article • Blood, December 2014, American Society of Hematology

Dr Massimo Martino
Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen

Article • Clinical Lymphoma Myeloma & Leukemia, December 2014, Elsevier

Dr Massimo Martino
Autologous stem cell transplantation in multiple myeloma is not dead but alive and well

Article • Expert Opinion on Biological Therapy, November 2014, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Plerixafor: what we still have to learn

Article • Expert Opinion on Biological Therapy, October 2014, Informa Healthcare

Dr Massimo Martino
Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Article • Expert Opinion on Biological Therapy, October 2014, Informa Healthcare

Dr Massimo Martino, Massimo Martino
High-dose chemotherapy for germ cell tumors: do we have a model?

Article • Expert Opinion on Biological Therapy, September 2014, Informa Healthcare

Dr Massimo Martino, Massimo Martino
A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study

Article • Leukemia & Lymphoma, July 2014, Taylor & Francis

Dr Massimo Martino
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study

Article • Biology of Blood and Marrow Transplantation, July 2014, Elsevier

Dr Massimo Martino, Massimo Martino
The effectiveness of therapy with octreotide LAR in combination treatment with zoledronic acid versus zoledronic acid alone.

Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

Dr Massimo Martino
Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients

Article • Expert Opinion on Pharmacotherapy, May 2014, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs

Article • Clinical Lymphoma Myeloma & Leukemia, April 2014, Elsevier

Dr Massimo Martino, Massimo Martino
Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

Article • Biology of Blood and Marrow Transplantation, April 2014, Elsevier

Dr Massimo Martino, Massimo Martino
Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization

Article • Expert Opinion on Biological Therapy, March 2014, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study

Article • Transfusion, March 2014, Wiley

Dr Massimo Martino
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

Article • British Journal of Haematology, October 2013, Wiley

Dr Massimo Martino
An old drug with a new future: bendamustine in multiple myeloma

Article • Expert Opinion on Pharmacotherapy, September 2013, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Article • Transfusion, June 2013, Wiley

Dr Massimo Martino
Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?

Article • Immunotherapy, June 2013, Future Medicine

Dr Massimo Martino, Massimo Martino
Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents

Article • Current Cancer Drug Targets, June 2013, Bentham Science Publishers

Massimo Martino, Dr Massimo Martino
Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma

Article • Expert Opinion on Biological Therapy, April 2013, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma

Article • Expert Opinion on Investigational Drugs, April 2013, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients

Article • Expert Opinion on Biological Therapy, September 2012, Informa Healthcare

Dr Massimo Martino
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry

Article • British Journal of Pharmacology, August 2012, Springer Science + Business Media

Dr Massimo Martino
Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program

Article • Expert Opinion on Biological Therapy, July 2012, Informa Healthcare

Dr Massimo Martino, Massimo Martino
Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?

Article • British Journal of Pharmacology, July 2012, Springer Science + Business Media

Dr Massimo Martino
Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art

Article • Expert Opinion on Biological Therapy, May 2012, Informa Healthcare

Dr Massimo Martino
A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease

Article • Haematologica, April 2012, Ferrata Storti Foundation (Haematologica)

Dr Massimo Martino
Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?

Article • Expert Opinion on Biological Therapy, March 2012, Informa Healthcare

Dr Massimo Martino
Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma

Article • Biology of Blood and Marrow Transplantation, February 2012, Elsevier

Dr Massimo Martino
Internal Iliac Artery Perforation following Bone Marrow Aspiration in a Patient with No Previously Identified Risk Factors: A Case Report and Review of the Literature

Article • Acta Haematologica, January 2012, Karger Publishers

Dr Massimo Martino
Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease

Article • Leukemia & Lymphoma, June 2011, Taylor & Francis

Dr Massimo Martino
Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells

Article • British Journal of Pharmacology, April 2011, Springer Science + Business Media

Dr Massimo Martino
Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis.

Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

Dr Massimo Martino
Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience

Article • British Journal of Pharmacology, February 2009, Springer Science + Business Media

Dr Massimo Martino
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry

Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

Dr Massimo Martino
Allogeneic hemopoietic stem cells donor complications: A single institution survey on sibling donors mobilized with G- CSF

Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

Dr Massimo Martino
r-HuEPO 40,000 U one time/week before high-dose melphalan allows a tandem autologous peripheral stem-cell transplantation without red blood cell transfusion in multiple myeloma patients: A pilot study

Article • Journal of Clinical Oncology, June 2007, American Society of Clinical Oncology (ASCO)

Dr Massimo Martino
Utility of the Clinical Practice of Admnistering Thrombophilic Screening and Antithrombotic Prophylaxis with Low-Molecular-Weight Heparin to Healthy Donors Treated with G-Csf for Mobilization of Peripheral Blood Stem Cells

Article • Tumori Journal, March 2007, SAGE Publications

Dr Massimo Martino
Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients

Article • European Journal Of Haematology, January 2007, Wiley

Dr Massimo Martino, Massimo Martino
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

Article • American Journal of Hematology, December 2006, Wiley

Dr Massimo Martino
Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients

Article • European Journal Of Haematology, November 2006, Wiley

Dr Massimo Martino
Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

Article • Journal of Clinical Apheresis, October 2006, Wiley

Dr Massimo Martino
Different γ/δ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation

Article • Leukemia Research, May 2006, Elsevier

Dr Massimo Martino
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

Article • British Journal of Cancer, March 2006, Springer Science + Business Media

Dr Massimo Martino
Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting

Article • Transplant Immunology, December 2005, Elsevier

Dr Massimo Martino
Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization

Article • Transfusion and Apheresis Science, October 2005, Elsevier

Dr Massimo Martino
'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization

Article • Transfusion Medicine, October 2005, Wiley

Dr Massimo Martino
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation

Article • Leukemia Research, August 2005, Elsevier

Dr Massimo Martino
Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor

Article • Transfusion Medicine, August 2005, Wiley

Dr Massimo Martino
Wernicke's encephalopathy after allogeneic stem cell transplantation

Article • British Journal of Pharmacology, March 2005, Springer Science + Business Media

Dr Massimo Martino
Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim

Article • Journal of Clinical Apheresis, January 2005, Wiley

Dr Massimo Martino
Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients

Article • Supportive Care in Cancer, October 2004, Springer Science + Business Media

Dr Massimo Martino
High-Dose Chemotherapy with Mitoxantrone + Melphalan and Autologous Stem Cell Rescue in Metastatic Breast Cancer Patients: A Study of Feasibility and Tolerability

Article • Tumori Journal, September 2003, SAGE Publications

Dr Massimo Martino
Differences in Transplant-Related Complications between Hematologic Malignancies and Solid Tumors Receiving High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation

Article • Tumori Journal, July 2003, SAGE Publications

Dr Massimo Martino
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients

Article • British Journal of Haematology, February 2003, Wiley

Dr Massimo Martino
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy

Article • British Journal of Pharmacology, November 2001, Springer Science + Business Media

Dr Massimo Martino
HIGH-DOSE ETOPOSIDE ENABLES THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WHO FAILED CYCLOPHOSPHAMIDE-INDUCED MOBILIZATION

Article • British Journal of Haematology, March 1998, Wiley

Dr Massimo Martino
Technical note: Chromosomal and mtDNA analysis of Oliver

Article • American Journal of Physical Anthropology, March 1998, Wiley

Dr Massimo Martino
Implications of solar flare charged particle, gamma ray and neutron observations: Rapporteur Paper II for the High Energy Solar Physics Workshop

Article • January 1996, American Institute of Physics

Dr Massimo Martino

Search Kudos

Main menu

Discover

Subjects on Kudos

Services and resources

Admin

All Stories